Implantica AG announced the FDA granted Premarket Approval (PMA) for its RefluxStop® device. The approval is a major regulatory milestone that de-risks commercialization and supports a more favorable outlook for the company’s medtech pipeline.
Implantica AG announced the FDA granted Premarket Approval (PMA) for its RefluxStop® device. The approval is a major regulatory milestone that de-risks commercialization and supports a more favorable outlook for the company’s medtech pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
